PET sales drive ADAC’s 3Q revenue increase

Article

ADAC Laboratories parlayed expansion of its distribution agreement with Hitachi in Japan and a three-year group purchasing agreement with Novation signed during the third quarter of fiscal 2000 into a net income of $4.6 million, compared to a net loss

ADAC Laboratories parlayed expansion of its distribution agreement with Hitachi in Japan and a three-year group purchasing agreement with Novation signed during the third quarter of fiscal 2000 into a net income of $4.6 million, compared to a net loss for the third quarter of 1999 of $5.4 million.

The Novation contract is expected to result in purchases of $15 million in PET and nuclear medicine imaging equipment during the first year of the deal.

Texas-based Novation is the healthcare industry’s largest purchasing organization. The ADAC contract was the result of competitive public bids.

Hitachi Medical Systems is now ADAC’s exclusive distributor in Japan of its PET imaging systems, as well as its nuclear medicine products and its radiation therapy planning system.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.